Cytek Biosciences, Inc. CTKB
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 5.50% | 5.44% | 3.61% | 0.52% | -2.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.50% | 5.44% | 3.61% | 0.52% | -2.18% |
| Cost of Revenue | 5.63% | 11.33% | 11.05% | 8.60% | 0.98% |
| Gross Profit | 5.38% | 0.51% | -2.49% | -5.98% | -4.77% |
| SG&A Expenses | 20.14% | 23.10% | 20.71% | 17.51% | 6.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.24% | 14.03% | 11.83% | 9.46% | 1.68% |
| Operating Income | -46.77% | -76.65% | -77.16% | -96.78% | -34.50% |
| Income Before Tax | -157.99% | -439.82% | -350.93% | -423.62% | -30.02% |
| Income Tax Expenses | 1,646.38% | 3,527.76% | 1,060.21% | 11,368.13% | -52.23% |
| Earnings from Continuing Operations | -533.36% | -1,158.83% | -557.69% | -1,005.48% | -26.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -533.36% | -1,158.83% | -557.69% | -1,005.48% | -26.19% |
| EBIT | -46.77% | -76.65% | -77.16% | -96.78% | -34.50% |
| EBITDA | -59.87% | -105.05% | -108.93% | -146.46% | -45.69% |
| EPS Basic | -524.95% | -1,132.42% | -569.06% | -1,065.02% | -29.32% |
| Normalized Basic EPS | -160.73% | -443.09% | -357.29% | -453.41% | -33.57% |
| EPS Diluted | -500.95% | -1,036.40% | -534.75% | -911.26% | -29.25% |
| Normalized Diluted EPS | -160.73% | -443.09% | -357.29% | -453.41% | -33.57% |
| Average Basic Shares Outstanding | 0.94% | -0.29% | -1.64% | -2.19% | -2.85% |
| Average Diluted Shares Outstanding | 0.94% | -0.63% | -1.97% | -2.53% | -3.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |